SYSTEM AND METHOD FOR ELECTRONIC IDENTIFICATION OF BIOMARKERS ASSOCIATED WITH PATHOLOGY

1 . A system for electronic identification of one or more biomarkers associated with a pathology, comprising:

a processor configured to:

receive an expression data comprising a plurality of datasets related to different physiological conditions of a plurality of subjects;

utilize a predefined degenerative model to generate a Transcription Factor (TF)-target interaction information based on the received expression data;

execute the predefined degenerative model to generate a Gene Regulatory Network (GRN) based on the TF-target interaction information, wherein the GRN comprises a plurality of TFs and a plurality of targets as two or more nodes, and a plurality of relationships among the plurality of TFs and the plurality of targets as one or more edges;

construct a hierarchical network defining hierarchical relationships among the two or more nodes and the one or more edges of the GRN;

prioritize a set of TFs and a set of targets among the plurality of TFs and the plurality of targets, respectively, using a Protein-Protein Interaction (PPI) network; and

construct a modified GRN based on the prioritized set of TFs and the prioritized set of targets to identify the one or more biomarkers associated with the pathology.

2 . The system according to claim 1 , wherein the processor is further configured to:

execute a Strongly Connected Components (SCC) operation in the hierarchical network to generate one or more directed acyclic graphs;

traverse the generated one or more directed acyclic graphs using one of: a Breadth First Search (BFS) operation, a Shortest Path (SP) operation and a Depth First Search (DFS) operation to determine distance among the two or more nodes of the GRN; and

assign a hierarchical score to each of the two or more nodes of the GRN using a cumulative node removal technique to quantify a degree of hierarchy in the GRN.

3 . The system according to claim 2 , wherein the processor is further configured to:

identify one or more master regulator nodes among the two or more nodes of the GRN based on the assigned hierarchical score to each of the two or more nodes of the GRN.

4 . The system according to claim 2 , wherein the processor is further configured to:

identify one or more regulated or dysregulated targets among the two or more nodes of the GRN based on the assigned hierarchical score to each of the two or more nodes of the GRN.

5 . The system according to claim 1 , wherein the processor is further configured to:

identify one or more clusters of the plurality of targets, wherein each cluster belongs to a specific data type; and

correlate the identified one or more clusters of the plurality of targets with one or more of the plurality of TFs in the GRN.

6 . The system according to claim 1 , wherein the generation of the TF-target interaction information comprises normalization of a plurality of databases resulting to a normalized database.

7 . The system according to claim 1 , wherein the predefined degenerative model is an autoencoder model.

8 . The system according to claim 1 , wherein the expression data comprises either high sequencing throughput (HTS) data, or a micro-array data or a single cell sorting, RNA extraction, reverse transcription, amplification, library construction, sequencing and subsequent bioinformatic analysis (scRNA-seq) data.

9 . The system according to claim 1 , wherein the modified GRN is one of: a linear GRN, a staggered GRN and a layered GRN.

10 . The system according to claim 1 , wherein the processor is further configured to:

generate a first GRN for a drug treated person;

generate a second GRN for a non-treated person;

overlay the first GRN over the second GRN to identify alterations at a node level and an edge level; and

identify one or more highly active edges and one or more inactive edges between the first GRN and the second GRN based on the alterations at the node level and at the edge level.

11 . The system according to claim 10 , wherein the first GRN is separate from the second GRN.

12 . The system according to claim 10 , wherein the processor is further configured to identify one or more of: a prognostic biomarker, or a drug response biomarker, or a drug safety biomarker, or a predictive biomarker based on the alterations at the node level and at the edge level.

13 . A method of electronic identification of one or more biomarkers associated with a pathology, comprises:

receiving, by a processor, an expression data comprising a plurality of datasets related to different physiological conditions of a plurality of subjects;

utilizing, by the processor, a predefined degenerative model to generate a Transcription Factor (TF)-target interaction information based on the received expression data;

executing, by the processor, the predefined degenerative model to generate a Gene Regulatory Network (GRN) based on the TF-target interaction information, wherein the GRN comprises a plurality of TFs and a plurality of targets as two or more nodes, and a plurality of relationships among the plurality of TFs and the plurality of targets as one or more edges;

constructing, by the processor, a hierarchical network defining hierarchical relationships among the two or more nodes and the one or more edges of the GRN;

prioritizing, by the processor, a set of TFs and a set of targets among the plurality of TFs and the plurality of targets, respectively, using a Protein-Protein Interaction (PPI) network; and

constructing, by the processor, a modified GRN based on the prioritized set of TFs and the prioritized set of targets to identify the one or more biomarkers associated with the pathology.

14 . The method according to claim 13 , wherein the method further comprises:

executing, by the processor, a Strongly Connected Components (SCC) operation in the hierarchical network to generate one or more directed acyclic graphs;

traversing, by the processor, the generated one or more directed acyclic graphs using one of: a Breadth First Search (BFS) operation, a Shortest Path (SP) operation and a Depth First Search (DFS) operation to determine distance among the two or more nodes of the GRN; and

assigning, by the processor, a hierarchical score to each of the two or more nodes of the GRN using a cumulative node removal technique to quantify degree of hierarchy in the GRN.

15 . The method according to claim 14 , wherein the method further comprises:

identifying, by the processor, one or more master regulator nodes among the two or more nodes of the GRN based on the assigned hierarchical score to each of the two or more nodes of the GRN.

16 . The method according to claim 14 , wherein the method further comprises:

identifying, by the processor, one or more regulated or dysregulated targets among the two or more nodes of the GRN based on the assigned hierarchical score to each of the two or more nodes of the GRN.

17 . The method according to claim 13 , wherein the method further comprises:

identifying, by the processor, one or more clusters of the plurality of targets, wherein each cluster belongs to a specific data type; and

correlating, by the processor, the identified one or more clusters of the plurality of targets with one or more of the plurality of TFs in the GRN.

18 . The method according to claim 13 , wherein the method further comprises:

generating, by the processor, a first GRN for a drug treated person;

generating, by the processor, a second GRN for a non-treated person;

overlaying, by the processor, the first GRN over the second GRN to identify alterations at a node level and an edge level; and

identifying, by the processor, one or more highly active edges and one or more inactive edges between the first GRN and the second GRN based on the alterations at the node level and the edge level.

19 . The method according to claim 18 , wherein the first GRN is separate from the second GRN.

20 . The method according to claim 18 , wherein the method further comprises identifying, by the processor, one or more of: a prognostic biomarker, or a drug response biomarker, or a drug safety biomarker, or a predictive biomarker based on the alterations at the node level and at the edge level.